Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05715931
Other study ID # IIT20220076C-R1
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date February 28, 2023
Est. completion date March 1, 2028

Study information

Verified date March 2023
Source First Affiliated Hospital of Zhejiang University
Contact Jiren Yu
Phone 0086-0571-87237931
Email yujr0909@zju.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a prospective, single arm, multi-center phase II clinical trial designed to evaluate the efficacy and safety of perioperative chemotherapy with FLOT regimen and trastuzumab in combination with toripalimab in participants with resectable HER2 positive locally advanced gastric or esophagogastric junction adenocarcinoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date March 1, 2028
Est. primary completion date March 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Voluntary participation in the clinical study; fully understands and is informed of the study and has signed the Informed Consent Form (ICF). - The gender is not limited. Age: = 18 years and = 80 years old. - Gastric or esophagogastric junction adenocarcinoma confirmed by pathology. - HER2-positive status defined as either IHC score of 3+ or IHC 2+ with amplification proven by fluorescent in situ hybridization (FISH) based on pretreatment endoscopic biopsies. - Clinical stage at presentation: cT2-T4b, N+/-, M0 as determined by AJCC staging system, 8th edition. - The definition of metastatic lymph nodes: a lymph node must be = 10mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm) according to the guideline of Response Evaluation Criteria in Solid Tumours (RECIST version 1.1) - Participants with a performance status of 0 ~ 1 on the Eastern Cooperative Oncology Group (ECOG) within 7 days before the first dose of study treatment. - Life expectancy = 6 months. - Agreement of providing pretreatment endoscopic biopsies specimens and surgical specimens for biomarker analysis, as well as the peripheral blood, feces and urine sample. - The functions of the vital organs meet requirements as follow (within 14 days before the first dose of study treatment, participant has not received treatment of recombinant human thrombopoietin or granulocyte stimulating factor): 1. Hematological function: - White blood cell count (WBC): 3.5 × 10 ^ 9 / L ~12.0 × 10 ^ 9 / L; - Absolute neutrophil count (ANC) = 1.5 × 10 ^ 9 / L; - Platelet count (PLT) = 100 × 10 ^ 9 / L; - Hemoglobin (Hb) = 90 g / L. 2. Hepatic function: - Total bilirubin (TBIL) = 1.5 × ULN (upper limit of normal); - Aspartate aminotransferase (AST) = 2.5 × ULN; - Alanine aminotransferase (ALT) = 2.5 × ULN; - Albumin (ALB) = 30 g / L. 3. Renal function: - Creatinine (Cr) = 1.5 × ULN, or creatinine clearance = 60 ml / min for those with creatinine level > 1.5 × ULN. 4. Coagulation function: - International normalized ratio (INR) = 1.5; - Prothrombin time (PT) and activated partial thromboplastin time (APTT) = 1.5 × ULN. 5. Cardiac function: - The left ventricular ejection fraction (LVEF) value = 55 %, as assessed by echocardiography - Female of childbearing age must meet requirements: urine or serum pregnancy test must be negative within 7 days before the first dose of study treatment, and she must agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer, and should not be breastfeeding. For the male participants must meet requirements: agree to use adequate contraception methods or keep abstinence (starting with the ICF is signed through 120 days after the last dose of toriplimab, or 210 days after the last dose of trastuzumab, or 180 days after the last dose of chemotherapy, whichever is longer). Exclusion Criteria: - Prior systemic therapy for treatment of gastric cancer (surgery, chemotherapy, radiotherapy, targeted therapy or immunotherapy). - Previous or concurrent have other active malignant tumors within the past 5 years (except for basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate cancer or cervical cancer or breast cancer in situ that has undergone curative therapy). - Participants with gastric outlet obstruction, or unable for oral take, or severe gastrointestinal bleeding. - Myocardial infarction within 6 months before the first dose of study treatment, uncontrolled angina, arrhythmia which need medical intervention (including but not limited to cardiac pacemaker), congestive heart failure (New York Heart Association (NYHA) class III or IV). - Existence of chronic diarrhea (watery diarrhea: = 5 times per day). - Participants with active infection within 14 days before the first dose of study treatment which need medical intervention. - Participants with active tuberculosis. - Previous or concurrent diagnosed with interstitial lung disease by imaging or symptoms. - Any of the following test is positive: Human Immunodeficiency Virus (HIV) antibody, Hepatitis B surface Antigen (HBsAg), or Hepatitis C Virus (HCV) antibody. - Participants who need long-term systemic steroid therapy (> 10 mg/d prednisone equivalent) or any other form of immunosuppressive therapy within 14 days before the first dose of study treatment or during the study period. - Concurrent or previous have severe allergic reaction to any antibody-based drugs. - Existence of any concurrent autoimmune disease, excepting participants with diabetes mellitus type I, hypothyroidism requiring only hormone replacement therapy. - Receive live vaccines within 28 days before the first dose of study treatment or during the study period, excepting inactivated viral vaccines for seasonal influenza. - Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation. - Existence of systemic disease that is difficult to control despite treatment with several agents, for example, diabetes mellitus, hypertension, etc. - Existence of other serious physical or mental diseases or serious laboratory abnormalities that may increase the risk of participating in the study. Participants who were judged unsuitable as subjects of this trial by investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Toripalimab
Toripalimab, 240 mg IV infusion on Day 1 of each 21 day cycle for 3 cycles prior to surgery and 3 cycles after surgery.
Trastuzumab
Trastuzumab, 8 mg/kg IV loading dose at 1st administration and then 6 mg/kg IV on Day 1 of each 21 day cycle for 3 cycles before surgery and 3 cycles after surgery. The first administration of trastuzumab after surgery should also be given at the loading dose of 8 mg/kg.
5-FU, leucovorin, docetaxel, oxaliplatin (FLOT)
Pre-operative treatment 4 cycles and post-operative treatment 4 cycles: Docetaxel 50 mg/m², IV on day 1 of each 14 day cycle; Oxaliplatin 85 mg/m² , IV on day 1 of each 14 day cycle; Leucovorin 200 mg/m² or Levoleucovorin 100 mg/m², IV on day 1 of each 14 day cycle; 5-FU 2600 mg/m², IV over 24 h on day 1 of each 14 day cycle.

Locations

Country Name City State
China The First Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China The Second Affiliated Hospital, College of Medicine, Zhejiang University Hangzhou Zhejiang
China Huzhou Central Hospital Huzhou Zhejiang
China Lishui Central Hospital Lishui Zhejiang
China Ningbo First Hospital Ningbo Zhejiang
China Ningbo Medical Center LiHuiLi Hospital Ningbo Zhejiang
China Ningbo Second Hospital Ningbo Zhejiang
China Taizhou Hospital Taizhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Yu jiren

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of pathological complete responses (pCR) Percentage of patients with pCR referring to the total number of enrolled and eligible patients, as evaluated centrally by a reference pathologist. From enrollment to surgery after pre-operative treatment (up to approximately 24 months)
Secondary Overall survival The duration of overall survival (OS) will be determined by measuring the time interval from enrollment to the end of follow up or death from any cause From enrollment to the end of follow up or death from any cause (up to approximately 60 months)
Secondary Progression-free survival Progression-free survival (PFS) will be defined as the time from enrollment to the end of follow up or the time of disease progression or relapse or death from any cause From enrollment to the end of follow up or the time of disease progression or relapse or death from any cause (up to approximately 60 months)
Secondary The incidences and types of adverse events (AE) and severe adverse events (SAE) The incidences and types of adverse events that occur during treatment will be evaluated according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.3 From enrollment to 90-day after the last dose administration (up to approximately 27 months)
See also
  Status Clinical Trial Phase
Recruiting NCT05070598 - Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer Phase 2
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Completed NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT05619016 - [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors Phase 2
Not yet recruiting NCT05586061 - First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer Phase 2
Active, not recruiting NCT05190445 - Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma Phase 2
Recruiting NCT05982834 - Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC Phase 1/Phase 2
Not yet recruiting NCT05313906 - RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer Phase 2
Recruiting NCT06328738 - ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Phase 1
Recruiting NCT04520295 - ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Recruiting NCT04319757 - ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors Phase 1
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Recruiting NCT06253650 - Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease Phase 2
Recruiting NCT05955833 - 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study Phase 1
Not yet recruiting NCT06414733 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Active, not recruiting NCT05555251 - BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors Phase 1/Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Not yet recruiting NCT06439550 - Adjuvant Treatment With Serplulimab,Trastuzumab and SOX in the HER-2 Positive GC/GEJC Phase 2
Recruiting NCT05514717 - A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 Phase 1
Terminated NCT05091528 - A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers Phase 1/Phase 2